UroGen Pharma

Yahoo Finance • last month

As Terns Stock Soars 1,400%, What Does One Fund's $5.2 Million Sale Signal to Investors?

On February 17, 2026, Acorn Capital Advisors reported selling 225,000 shares of Terns Pharmaceuticals(NASDAQ:TERN), an estimated $5.20 million trade based on quarterly average pricing. What happened According to a filing with the Securit... Full story

Yahoo Finance • last month

This New $7 Million Bet Targets a CNS Drug Maker With Phase 3 Trial Underway and 27% Stock Gain

On February 17, 2026, Superstring Capital Management disclosed a new position in Axsome Therapeutics(NASDAQ:AXSM), acquiring 37,433 shares worth $6.84 million in the fourth quarter. What happened According to a Securities and Exchange Co... Full story

Yahoo Finance • last month

This $6 Million Bet Adds a Brain Health Biotech to Portfolio Dominated by Clinical Stage Names

On February 17, 2026, Superstring Capital Management disclosed a new position in Definium Therapeutics(NASDAQ:DFTX), acquiring 425,202 shares in the fourth quarter. What happened According to a SEC filing dated February 17, 2026, Superst... Full story

Yahoo Finance • last month

This Biotech Fund Sold $8 Million of Terns Stock Last Quarter, but Here's Why It Still Seems Very Bullish

On February 17, 2026, Superstring Capital Management reported selling 345,869 shares of Terns Pharmaceuticals(NASDAQ:TERN) in the fourth quarter, an estimated $7.99 million trade based on quarterly average pricing. What happened Accordin... Full story

Yahoo Finance • 2 months ago

UroGen (URGN) Q4 2025 Earnings Call Transcript

Image source: The Motley Fool. Date Monday, March 2, 2026 at 10 a.m. ET Call participants President and Chief Executive Officer — Elizabeth A. Barrett Chief Medical Officer — Mark P. Schoenberg Chief Commercial Officer — David Lin Chie... Full story

Yahoo Finance • 2 months ago

Here are the major earnings before the open Monday

Major earnings expected before the bell on Monday include: * Norwegian Cruise Line Holdings Ltd. (NCLH [https://seekingalpha.com/symbol/NCLH]) * Uniti Group (UNIT [https://seekingalpha.com/symbol/UNIT]) * The Progressive Corporation... Full story

Yahoo Finance • 5 months ago

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PRINCETON, N.J., Dec. 05, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the gra... Full story

Yahoo Finance • 5 months ago

UroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare Conference

PRINCETON, N.J., Nov. 25, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it... Full story

Yahoo Finance • 6 months ago

UroGen outlines $1B ZUSDURI peak revenue ambition as adoption set to accelerate with permanent J-code in 2026

Earnings Call Insights: UroGen Pharma Ltd. (URGN) Q3 2025 MANAGEMENT VIEW * CEO Elizabeth Barrett highlighted the progress of the ZUSDURI launch and noted, "The preliminary demand revenue for October is more than double the previous 3... Full story

Yahoo Finance • 6 months ago

UroGen Reports 77.8% Three-Month Complete Response Rate from Phase 3 UTOPIA Trial of UGN-103 and Receives FDA Agreement on NDA Submission Strategy in Recurrent LG-IR-NMIBC Based on UTOPIA Trial

PRINCETON, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced robust... Full story

Yahoo Finance • 6 months ago

UroGen Pharma to Report Third Quarter 2025 Financial Results on Thursday, November 6th, 2025

PRINCETON, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it... Full story

Yahoo Finance • 7 months ago

ZUSDURI™ Clinical Review Published in Reviews in Urology™ Highlights Durable Efficacy and Manageable Safety Profile in Recurrent Low-Grade, Intermediate-Risk Non–Muscle Invasive Bladder Cancer

PRINCETON, N.J., Oct. 02, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company focused on developing and commercializing innovative solutions for urothelial and specialty cancers, today announced the publication... Full story

Yahoo Finance • 9 months ago

UroGen Pharma CMO Schoenberg sells $176k in shares

Mark Schoenberg, Chief Medical Officer of UroGen Pharma Ltd (NASDAQ:URGN), a company with impressive gross margins of 88.5% and a market capitalization of $902 million, sold 10,000 ordinary shares of the company on August 11, 2025. The sha... Full story

Yahoo Finance • 9 months ago

Sector Update: Health Care Stocks Decline Late Afternoon

Health care stocks were slipping late Thursday afternoon, with the NYSE Health Care Index down 1% an PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 9 months ago

UroGen Pharma GAAP EPS of -$1.05 misses by $0.23, revenue of $24.2M beats by $1.07M

* UroGen Pharma press release [https://seekingalpha.com/pr/20193018-urogen-pharma-expands-commercial-portfolio-with-launch-of-zusduri-and-reports-second-quarter] (NASDAQ:URGN [https://seekingalpha.com/symbol/URGN]): Q2 GAAP EPS of -$1.05... Full story

Yahoo Finance • 9 months ago

UroGen Pharma Q2 2025 Earnings Preview

* UroGen Pharma (NASDAQ:URGN [https://seekingalpha.com/symbol/URGN]) is scheduled to announce Q2 earnings results on Thursday, August 7th, before market open. The consensus EPS Estimate is -$0.83 [https://seekingalpha.com/symbol/URGN/ea... Full story

Yahoo Finance • 9 months ago

UROGEN FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds UroGen Pharma (URGN) Investors of the July 28th Deadline and Urges Investors in to Inquire About Their Rights in Class Action Lawsuit

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In UroGen Pharma (URGN) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in UroGenbetween July... Full story

Yahoo Finance • 9 months ago

UroGen's bladder cancer treatment shows promise for home administration

PRINCETON, N.J. - UroGen Pharma Ltd. (NASDAQ:URGN), a pharmaceutical company with an impressive gross profit margin of nearly 90%, announced Monday that a Phase 3b study has demonstrated the feasibility of administering its bladder cancer... Full story

Yahoo Finance • 9 months ago

UROGEN DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds UroGen Pharma (URGN) Investors of the July 28th Deadline and Urges Investors to Inquire About Their Rights in Class Action Lawsuit

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In UroGen Pharma (URGN) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in UroGenbetween July... Full story

Yahoo Finance • 9 months ago

INVESTOR ALERT: Holzer & Holzer, LLC Reminds Investors of July 28, 2025 Lead Plaintiff Deadline in the UroGen Pharma Ltd. (URGN) Class Action – Investors With Significant Losses Encouraged to Contact the Firm

ATLANTA, July 21, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDAQ: URGN). The lawsuit alleges that Defendants made materially false and/or misleadi... Full story